Recent News

• 02.11.2026 - Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
• 02.05.2026 - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• 02.02.2026 - Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026
• 01.22.2026 - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
• 01.21.2026 - Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 01.30.2026 - 8-K Current report
• 01.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.26.2026 - 144 Report of proposed sale of securities
• 01.26.2026 - 144 Report of proposed sale of securities
• 01.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.26.2026 - 144 Report of proposed sale of securities
• 01.26.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.26.2026 - 144 Report of proposed sale of securities
• 01.20.2026 - 4 Statement of changes in beneficial ownership of securities